CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Novel Biologics  /  Itolizumab

NOVEL PIPELINE

Itolizumab

The world’s first novel anti-CD6 monoclonal antibody

Itolizumab was launched in India in 2013 under the brand name ALZUMAb™. Itolizumab is Biocon’s second ‘lab to market’ novel biologic after Nimotuzumab and offers a ‘best-in-class’ biologic drug for acute psoriasis. ALZUMAb™ offers a less aggressive dosing regimen and a longer treatment free period and has seen encouraging outcomes. Our research also indicated Itolizumab’s potential in treating several autoimmune conditions.

Itolizumab has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.

Through an exclusive partnership, Biocon has licensed out the rights for Itolizumab to U.S.-based biotechnology company Equillium for the markets of U.S., Canada, Australia and New Zealand. Itolizumab is currently being evaluated in multiple clinical trials in patients with severe diseases, including acute graft-versus-host disease (aGVHD), lupus / lupus nephritis and uncontrolled asthma.

Out-licensing partnership with Equillium

Biocon outlicensed Itolizumab to U.S.-based biotechnology company Equillium in 2017. Itolizumab holds the potential of a ‘pipeline in a product’ with multiple high-value indications. Equillium has three clinical studies underway across the globe for Itolizumab in acute graft-versus-host disease (aGVHD), severe Asthma and Lupus Nephritis.

The scope of our licensing agreement with Equillium for Itolizumab, which initially covered U.S. and Canada, was extended to include Australia and New Zealand in FY20.

Equillium is making steady progress in the Phase 1b clinical trials for Itolizumab in the first-line treatment of acute graft-versus-host disease (aGVHD). The overall Phase 1b topline data is expected during the first half of 2021.

null

Itolizumab approved for emergency use in Covid-19 in India

A pivotal study from Itolizumab significantly reduced mortality in moderate to severe ARDS (Acute Respiratory Distress Syndrome) patients hospitalised with COVID-19, in India.

View Peer-Reviewed Article on Itolizumab >>

Read More about Biocon’s fight against Covid-19 >>

MOA of Itolizumab-Covid-19

Itolizumab MOA
FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
BOARD OF DIRECTORS
PRESS RELEASES
Share
Previous Next
Close
Test Caption
Test Description goes like this